This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Sumit Yadav Andrew J. Hodge Allan D. Hilless Peter D. Skillington Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Yadav, S. Articles by Skillington, P. D. Search for Related Content PubMed PubMed Citation Articles by Yadav, S. Articles by Skillington, P. D. Related Collections Valve disease

Outcomes with Toronto stentless porcine aortic valve: the Australian experience

^a Departments of Cardiothoracic Surgery, Fremantle Hospital, Fremantle, WA (6160), Australia
^b Departments of Cardiothoracic Surgery, Wesley Hospital, Brisbane, Australia
^c Departments of Cardiothoracic Surgery, The Royal Melbourne Hospital, Melbourne, Australia

*Corresponding author. Tel.: +61-8-9431 3337; fax: +61-8-9431 2915.

E-mail address: s_yadava{at}rediffmail.com (S. Yadav).

The purpose of this study is to describe the Australian experience with TSPV in the aortic position in 543 patients followed for up to 8 years. Prospectively collected data were reviewed. The average age was 73.5 years, with 74.4% older than 70 years. Eighty-five percent of valves were calcified and 79.5% stenotic. Most valves implanted (79.3%) were sizes 25, 27, or 29 mm. Concomitant coronary bypass was performed in 45.3% of patients. Total cumulative follow-up for the 543 patients was 2131 patient years. At 6 years, 82.1% and at 8 years, 76.3% were in New York Heart Association class I, 55% had no aortic insufficiency. The average mean systolic gradient for all valves at 6 years was 7.4 mmHg. The effective orifice area varied from 1.7 cm² (23-mm valve) to 1.96 cm² (29-mm valve). Actuarial survival at 8 years was 79.3%. Freedom from valve-related deaths was 93.2%. There was one instance of primary tissue valve failure during follow-up, with 93.3% freedom from explant. The early hemodynamic benefits of the TSPV are well maintained during more than 8 years of follow-up, without evident significant valvular dysfunction. Longer follow-up time is required to validate durability.

Key Words: Heart valves; Stentless; Aortic valve replacement; Xenograft